Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series
September 20 2017 - 6:05AM
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
announced today that members of the senior management team will
provide a corporate update at the 2017 Leerink Partners Rare
Disease Roundtable Series on Wednesday, September 27, 2017 at 10:00
a.m. ET at the Lotte New York Palace Hotel in New York City, NY.
The live audio and subsequent archived webcasts
of the Company's presentations will be accessible from the
Company's investor relations website, http://ir.achillion.com. The
audio recording will be archived for 30 days following the live
presentation. Please connect to Achillion's website several minutes
prior to the start of the presentation to ensure adequate time for
any software downloads that may be necessary.
About Achillion
Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is
a science-driven, patient-focused company seeking to leverage its
strengths across the continuum from discovery to commercialization
in its goal of providing better treatments for people with serious
diseases. The company employs a highly-disciplined discovery and
development approach that has allowed it to pursue best-in-class
oral antiviral therapy for chronic hepatitis C (HCV) and build a
platform of potent and specific complement factor D inhibitors for
AP-mediated diseases. Achillion is rapidly advancing its efforts to
become a fully-integrated pharmaceutical company with a goal of
bringing life-saving medicines to patients with rare diseases. More
information is available
at http://www.achillion.com.
|
Investors &
Media:Glenn SchulmanAchillion Pharmaceuticals, Inc.Tel.
(203) 752-5510gschulman@achillion.com |
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Sep 2023 to Sep 2024